101 related articles for article (PubMed ID: 18001321)
1. The ARMYDA trials (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) at Campus Bio-Medico University: rationale, results and future horizons.
di Sciascio G
Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():41-3. PubMed ID: 18001321
[TBL] [Abstract][Full Text] [Related]
2. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy.
Patti G; Chello M; Pasceri V; Colonna D; Nusca A; Miglionico M; D'Ambrosio A; Covino E; Di Sciascio G
J Am Coll Cardiol; 2006 Oct; 48(8):1560-6. PubMed ID: 17045888
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.
Pasceri V; Patti G; Nusca A; Pristipino C; Richichi G; Di Sciascio G;
Circulation; 2004 Aug; 110(6):674-8. PubMed ID: 15277322
[TBL] [Abstract][Full Text] [Related]
4. Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations.
Rihal CS; Raco DL; Gersh BJ; Yusuf S
Circulation; 2003 Nov; 108(20):2439-45. PubMed ID: 14623791
[No Abstract] [Full Text] [Related]
5. DUAAL: atorvastatin provided an unexpectedly potent heart benefit in patients with chronic stable angina.
Cardiovasc J Afr; 2008; 19(3):174. PubMed ID: 18568187
[No Abstract] [Full Text] [Related]
6. Benefits of atorvastatin in cholesterol lowering.
Farmer JA
Curr Atheroscler Rep; 2003 Mar; 5(2):94-5. PubMed ID: 12573192
[No Abstract] [Full Text] [Related]
7. [AVERT [The Atorvastatin versus Revascularization Treatment]].
Mokuno H
Nihon Rinsho; 2001 Mar; 59 Suppl 3():436-41. PubMed ID: 11347110
[No Abstract] [Full Text] [Related]
8. [Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention].
Patti G; Pasceri V; Nusca A; Di Sciascio G
Ital Heart J Suppl; 2005 Sep; 6(9):553-60. PubMed ID: 16281714
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin (Lipitor).
Tucker G
Conn Med; 1998 May; 62(5):283-5. PubMed ID: 9639958
[No Abstract] [Full Text] [Related]
10. Effects of atorvastatin on carotid intima media thickness: a meta-analysis of randomized controlled trials.
Takagi H; Yamamoto H; Iwata K; Goto SN; Umemoto T
Int J Cardiol; 2012 Aug; 159(1):69-72. PubMed ID: 22575629
[No Abstract] [Full Text] [Related]
11. Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy.
Patti G; Chello M; Gatto L; Alfano G; Miglionico M; Covino E; Di Sciascio G
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):795-800. PubMed ID: 20613550
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease.
Kiberd BA
Nat Clin Pract Nephrol; 2006 Jul; 2(7):354-5. PubMed ID: 16932460
[No Abstract] [Full Text] [Related]
13. Letter by Shroff and Orlandi regarding article, "Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac Surgery) study".
Shroff GR; Orlandi QG
Circulation; 2007 Apr; 115(15):e404; author reply e405. PubMed ID: 17438159
[No Abstract] [Full Text] [Related]
14. Letter by Padfield et al regarding article, "Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac Surgery) study".
Padfield GJ; Hawkins NM; MacDonald MR
Circulation; 2007 Apr; 115(15):e403; author reply e405. PubMed ID: 17438158
[No Abstract] [Full Text] [Related]
15. Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study.
Veselka J; Zemánek D; Hájek P; Malý M; Adlová R; Martinkovicová L; Tesar D
Am J Cardiol; 2009 Sep; 104(5):630-3. PubMed ID: 19699335
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of randomized trials for effects of atorvastatin on renal function in chronic kidney disease.
Takagi H; Umemoto T
Int J Cardiol; 2011 Oct; 152(2):242-4. PubMed ID: 21764159
[No Abstract] [Full Text] [Related]
17. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin for reduction of myocardial damage during angioplasty trials.
Nusca A; Melfi R; Patti G; Di Sciascio G
J Cardiovasc Med (Hagerstown); 2010 Oct; 11(10):709-11. PubMed ID: 20815110
[No Abstract] [Full Text] [Related]
19. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
